Pancreatic Cancer

>

Latest News

Higher social vulnerability index was independently associated with lower odds of meeting at least one quality criterion in treatment for PDAC.
Disparities in Treatment/Survival Outcomes Observed in Metastatic PDAC

April 15th 2025

Higher social vulnerability index was independently associated with lower odds of meeting at least one quality criterion in treatment for PDAC.

Although the overall incidence of colorectal adenocarcinoma is decreasing, the reduction is primarily associated with patients 55 years and older.
Pancreatic/Colorectal Adenocarcinoma Rates Have Increased in Young Adults

April 15th 2025

Mitigating NALIRIFOX-Related Diarrhea May Extend Survival in Metastatic PDAC
Mitigating NALIRIFOX-Related Diarrhea May Extend Survival in Metastatic PDAC

April 12th 2025

Next-Generation Test Shows Sensitivity/Specificity in Pancreatic Cancer
Next-Generation Test Shows Sensitivity/Specificity in Pancreatic Cancer

March 26th 2025

Data from the phase 3 CABINET study support the approval of cabozantinib in patients with pancreatic neuroendocrine tumors.
FDA Approves Cabozantinib in Pancreatic/Extra-Pancreatic Neuroendocrine Tumors

March 26th 2025